AKBA — Akebia Therapeutics Share News
0.000.00%
Last trade - 00:00- $305.81m
- $337.17m
- $236.20m
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Akebia Therapeutics Inc - Akb-097 Phase 2 Rare Kidney Disease Basket Trial Scheduled To Begin In 2H 2026 With Initial Data Expected In 2027
Brief: Akebia Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Praliciguat
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Announces Establishment Of Rare Kidney Disease Pipeline
Brief: Q32 Bio Sells Complement Inhibitor Adx-097
Akebia Therapeutics Q3 revenue rises
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Akebia Therapeutics tumbles after FDA setback on anemia drug trial
Brief: Akebia Therapeutics Provides Update On Vafseo For Non-Dialysis Patients
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Akebia Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Akebia Therapeutics Q2 revenue smashes expectations
Akebia Therapeutics Inc expected to post a loss of 2 cents a share - Earnings Preview
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule